Video blog: HER2-targeted agents

During this in-person event, over 500 attendees celebrated the remarkable efforts made by oncology nurses in the care of patients with cancer.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

At first, I wanted to avoid receiving chemotherapy at all costs, but I realized taking it would be the beginning of staying cancer-free.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

Treatment with Enhertu “is an unprecedented approval” for patients with HER2-positive solid tumors who did not have many options, an expert told CURE®.

Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.